Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : FDA THRESHOLD: LOWER-RISK BIOTECH INVESTING -- Ignore unavailable to you. Want to Upgrade?

To: opalapril who wrote (24)	10/7/1999 9:57:00 PM
From: LLCF	Respond to of 75

<. (1) Wait out promising drugs through all the trials and then buy as fast as you can when FDA approval is awarded or seems assured (a strategy that worked very well for everybody watching PFE bringing Viagra to the FDA); > Oopss.. PFE is not a biotech... check out CEPH, CORR chars... the stocks 'tanked' after approval, could have loaded up on all you wanted and then made 100+% in less than a year! < (3) Buy solid companies with long-term prospects after they suffer some unexpected or unwarranted hit owing to a non-fundamental, short-term problem; > Agree here.... and don't forget the old.... buy a basket of these. DAK

To: opalapril who wrote (24)	10/7/1999 9:59:00 PM
From: Edscharp	Read Replies (1) \| Respond to of 75

"isn't it fairly standard for a company accused of infringement to issue public denial statements?" Opal, It sure is SOP and initially I was concerned, but I had an opportunity to listen to the replay of the CEO in the telephone conference and I'm generally satisfied with his remarks. It was ImClone itself that "inadvertently" dredged this matter up while doing due diligence on a planned offering (see 2nd link below). Genentech is not claiming infringement of their patents. I was lucky. I'm glad you mentioned your 4-ways to invest. Though I concede your rules are reasonable I personally find them a bit too restrictive. I took a large position in ImClone for a two reasons. First, they had phenomenal results in P2 trials with C225 (I know, it sounds familiar to me too). I don't remember the particular stats now, but the C225 group had an incredible response rate which included many remissions to head and neck cancers. Further, the EGF factor, which C225 neutralizes, is implicated in as many as 1/3 of all the cancers. A potential blockbuster. Second, it was my intention to sell-off half my holdings prior to announcement of the P3 trial results and play into the inevitable speculative run-up in the stock. I wish I had done this on Xoma. I would've made good money on Xoma and still had a positon in it (waiting for the next debacle). Once in a while a company like ImClone comes along which is worth some additional risk. This is much the same reason why I invested in Xoma. If I invest in 10 Xoma/ImClone-type companies and I get just two or three companies that are 10-baggers I'm way ahead of the game. Management of risk comes in many flavors. imclone.com (Directions to telephone conference replay) siliconinvestor.com (News report on telephone confererence statements by CEO) Regards, Ed